KR20120117986A - 활성 약학적 성분 및 고도불포화지방산 에스테르로 이루어진 심혈관 질환 치료용 캡슐 - Google Patents

활성 약학적 성분 및 고도불포화지방산 에스테르로 이루어진 심혈관 질환 치료용 캡슐 Download PDF

Info

Publication number
KR20120117986A
KR20120117986A KR1020127015768A KR20127015768A KR20120117986A KR 20120117986 A KR20120117986 A KR 20120117986A KR 1020127015768 A KR1020127015768 A KR 1020127015768A KR 20127015768 A KR20127015768 A KR 20127015768A KR 20120117986 A KR20120117986 A KR 20120117986A
Authority
KR
South Korea
Prior art keywords
capsule
poly
polyunsaturated fatty
fatty acid
pharmaceutical
Prior art date
Application number
KR1020127015768A
Other languages
English (en)
Korean (ko)
Inventor
안토니오 파렌테 두에나
파올로 카르미나티
Original Assignee
지피 팜, 에스. 에이.
데피안떼 파마슈띠까 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지피 팜, 에스. 에이., 데피안떼 파마슈띠까 에스.에이. filed Critical 지피 팜, 에스. 에이.
Publication of KR20120117986A publication Critical patent/KR20120117986A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127015768A 2009-11-20 2010-11-19 활성 약학적 성분 및 고도불포화지방산 에스테르로 이루어진 심혈관 질환 치료용 캡슐 KR20120117986A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200931024 2009-11-20
ES200931024A ES2364011B1 (es) 2009-11-20 2009-11-20 Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.

Publications (1)

Publication Number Publication Date
KR20120117986A true KR20120117986A (ko) 2012-10-25

Family

ID=43498490

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015768A KR20120117986A (ko) 2009-11-20 2010-11-19 활성 약학적 성분 및 고도불포화지방산 에스테르로 이루어진 심혈관 질환 치료용 캡슐

Country Status (14)

Country Link
EP (1) EP2501365A2 (fr)
JP (1) JP2013511480A (fr)
KR (1) KR20120117986A (fr)
CN (1) CN102711735A (fr)
AR (1) AR079428A1 (fr)
AU (1) AU2010321248A1 (fr)
BR (1) BR112012011902A2 (fr)
CA (1) CA2781434A1 (fr)
ES (1) ES2364011B1 (fr)
IL (1) IL219874A0 (fr)
MX (1) MX2012005744A (fr)
RU (1) RU2012122886A (fr)
TW (1) TW201141469A (fr)
WO (1) WO2011060945A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142607A1 (fr) * 2013-03-14 2014-09-18 보령제약 주식회사 Médicament combiné pharmaceutique

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2014037832A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la dépression
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2013167992A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles inflammatoires
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168012A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles respiratoires
WO2013168002A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de l'asthme et de l'allergie
WO2013168033A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et methodes pour le traitement de maladies neurologiques
WO2013168000A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur sévère
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome des jambes sans repos et de la fibromyalgie
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168016A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013175344A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
CA2873098A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la sclerose en plaques
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
KR101414873B1 (ko) * 2012-06-28 2014-07-03 보령제약 주식회사 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
KR101391551B1 (ko) * 2012-07-10 2014-05-02 보령제약 주식회사 심부전증 예방, 완화 및 치료용 약학 조성물 및 이를 포함하는 복합제제
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
WO2014041445A2 (fr) * 2012-09-13 2014-03-20 Mahesh Kandula Compositions et procédés pour le traitement de l'hypertension et la gestion de la néphropathie diabétique
CN102895205A (zh) * 2012-11-09 2013-01-30 重庆市力扬医药开发有限公司 一种快速溶出的阿齐沙坦药物制剂
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3002735B1 (fr) * 2013-03-04 2015-07-03 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (fr) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
RU2577685C1 (ru) * 2014-09-19 2016-03-20 Александр Александрович Кролевец Способ получения нанокапсул лозартана калия в альгинате натрия
WO2016046835A1 (fr) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
WO2016051420A1 (fr) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
RU2605848C2 (ru) * 2014-10-10 2016-12-27 Александр Александрович Кролевец Способ получения нанокапсул лекарственных препаратов группы цефалоспоринов в интерфероне
EP3212626B1 (fr) 2014-10-27 2018-11-07 Cellix Bio Private Limited Séls á trois composants du ester monométhylique du acid fumarique avec pipérazine ou ethylene diamine pour le traitement de sclérose en plaques
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
RU2596476C1 (ru) * 2015-04-27 2016-09-10 Александр Александрович Кролевец Способ получения нанокапсул лекарственных растений, обладающих спазмолитическим действием
JP6298435B2 (ja) * 2015-10-28 2018-03-20 大原薬品工業株式会社 アンジオテンシンｉｉ受容体拮抗薬を含有する口腔内崩壊錠
CN106074542A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐软胶囊的制备方法
KR101914051B1 (ko) * 2018-07-13 2018-12-28 (주)바이오제닉스 숯이 함유된 이중 캡슐 및 이의 제조방법
CN114617264A (zh) * 2020-12-14 2022-06-14 深圳市前海小藻科技有限公司 具有高含量epa的植物胶囊制剂
WO2022145443A1 (fr) * 2020-12-28 2022-07-07 株式会社Cured Composition pharmaceutique pour le traitement d'une maladie rénale chronique

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (fr) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
TW284688B (fr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6417196B1 (en) 1998-06-05 2002-07-09 Warner-Lambert Company Stabilization of quinapril using magnesium oxide
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
HU226950B1 (en) 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2357982A1 (fr) 2001-09-28 2003-03-28 Bernard Charles Sherman Compositions solides contenant du ramipril
BR0306928A (pt) 2002-01-15 2004-11-09 Ranbaxy Lab Ltd Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
WO2004064834A1 (fr) 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Losartan amorphe co-precipite et posologies comprenant celui-ci
EP1653929A1 (fr) 2003-01-22 2006-05-10 Sandoz AG Composition pharmaceutique solide comprenant du ramipril
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
WO2005070398A2 (fr) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
WO2005079751A2 (fr) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de candesartan cilexetil
WO2005084648A1 (fr) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
WO2006135415A2 (fr) 2004-09-08 2006-12-21 University Of Florida Research Foundation, Inc. Micelles et nanoemulsions pour le traitement prophylactique et reactif de l'atherosclerose
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
MX2007005373A (es) 2004-11-05 2007-08-14 King Pharmaceuticals Res & Dev Composiciones estabilizadas de ramipril y metodos para elaborarlas.
WO2006076097A2 (fr) 2004-12-07 2006-07-20 Nektar Therapeutics Preparation non cristalline stable contenant du losartan
EP1674080A1 (fr) 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan
WO2006081518A2 (fr) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Excipients non aqueux non ioniques pour administration topique et par voie orale d'agents actifs lies a un support
CA2646131C (fr) * 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions et procedes permettant d'ameliorer la cachexie
GR1006875B (el) 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
EP2081550B2 (fr) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
US20070281000A1 (en) 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
WO2008001184A2 (fr) 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Composition solide
WO2008000040A1 (fr) 2006-06-30 2008-01-03 Alphapharm Pty Ltd Composition stabilisée comprenant des inhibiteurs de l'eca
WO2008012371A1 (fr) 2006-07-28 2008-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de formes amorphes et cristallines de candésartan cilexétil par chromatographie sur colonne
US20080152717A1 (en) 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
EP1952806A1 (fr) 2007-02-01 2008-08-06 Helm AG Procédé de préparation des produits d'absorption de candesartan
EP1997479A1 (fr) 2007-05-31 2008-12-03 Helm AG Formulations stabilisées contentant du candesartan cilexetil amorphe pour l'administration orale
KR20100111292A (ko) * 2008-01-10 2010-10-14 다케다 야쿠힌 고교 가부시키가이샤 캡슐 제제

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142607A1 (fr) * 2013-03-14 2014-09-18 보령제약 주식회사 Médicament combiné pharmaceutique
US9592233B2 (en) 2013-03-14 2017-03-14 Boryung Pharmaceutical Co., Ltd. Pharmaceutical combination drug

Also Published As

Publication number Publication date
CA2781434A1 (fr) 2011-05-26
WO2011060945A3 (fr) 2012-01-19
TW201141469A (en) 2011-12-01
ES2364011A1 (es) 2011-08-23
BR112012011902A2 (pt) 2017-10-10
AU2010321248A1 (en) 2012-06-07
IL219874A0 (en) 2012-07-31
RU2012122886A (ru) 2013-12-27
EP2501365A2 (fr) 2012-09-26
ES2364011B1 (es) 2013-01-24
AR079428A1 (es) 2012-01-25
WO2011060945A2 (fr) 2011-05-26
CN102711735A (zh) 2012-10-03
MX2012005744A (es) 2012-12-05
JP2013511480A (ja) 2013-04-04

Similar Documents

Publication Publication Date Title
KR20120117986A (ko) 활성 약학적 성분 및 고도불포화지방산 에스테르로 이루어진 심혈관 질환 치료용 캡슐
EP1803440B1 (fr) Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
JP5829607B2 (ja) ω３脂肪酸の配合製剤
EP2359817B1 (fr) Forme posologique solide s'administrant par voie orale qui contient des microcapsules sans soudure
KR101455413B1 (ko) 스타틴-캡슐화된 나노입자를 함유하는 약학적 조성물
AU2013387667B2 (en) Enteric coated multiparticulate composition with proteinaceous subcoat
CN103458880A (zh) 口服给药的单位剂型
WO2008084504A2 (fr) Composition pharmaceutique d'inhibiteurs du récepteur de l'angiotensine ii
JP2009541433A (ja) オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び１又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程
JP6151854B2 (ja) 心血管疾患の治療用経口製剤
WO2004080440A1 (fr) Procede servant a preparer une formulation en gelules dures contenant lansoprasole
JP4877899B2 (ja) 薬物徐放出性球状微粒子及びその製造方法

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid